ABBV vs PTGX
AbbVie vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
VS
PTGX
Protagonist Therapeutics, Inc.
70
Buy
| Metric | ABBV | PTGX |
|---|
| AI Score |
69
|
70
|
| Price |
$249.34
|
$155.12
|
| P/E Ratio |
70.28×
|
127.33×
|
| ROE |
-129.2%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
71.5%
|
99.9%
|
| Debt / Equity |
-11.93×
|
0.01×
|
| Dividend Yield |
2.7%
|
0.0%
|
| RSI (14) |
48.9
|
75.9
|
| Beta |
0.28
|
1.794
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ABBV versus PTGX.
PTGX leads by 1 points.
PTGX scores 70/100 (Buy) versus ABBV at 69/100 (Buy).
ABBV Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.20 across 84 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
PTGX Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Weekly RSI at 87 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 20.7% signals elevated volatility — Risk